Clinical trial
Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients…
NCT00352417 · Tallikut Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00352417 |
|---|---|
| Title | Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy |
| Official title | A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-Lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients With Carotid Stenosis Undergoing Elective Carotid Endarterectomy |
| Lead sponsor | Tallikut Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atherosclerosis |
| Intervention type | Drug |
| Interventions | VIA-2291, Placebo |
| Enrollment | 50 |
| Start date | Jul 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jul 14, 2006 |
| Last update posted | Jul 27, 2012 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: